JP2024525078A5 - - Google Patents
Info
- Publication number
- JP2024525078A5 JP2024525078A5 JP2024500173A JP2024500173A JP2024525078A5 JP 2024525078 A5 JP2024525078 A5 JP 2024525078A5 JP 2024500173 A JP2024500173 A JP 2024500173A JP 2024500173 A JP2024500173 A JP 2024500173A JP 2024525078 A5 JP2024525078 A5 JP 2024525078A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai
- sense strand
- antisense strand
- strand
- acetylgalactosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210089864 | 2021-07-08 | ||
| KR10-2021-0089864 | 2021-07-08 | ||
| PCT/KR2022/009984 WO2023282704A1 (ko) | 2021-07-08 | 2022-07-08 | Marc1 유전자를 표적으로 하는 rnai 제제 및 이의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525078A JP2024525078A (ja) | 2024-07-09 |
| JP2024525078A5 true JP2024525078A5 (enExample) | 2026-01-20 |
| JP7853399B2 JP7853399B2 (ja) | 2026-04-28 |
Family
ID=84801791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500173A Active JP7853399B2 (ja) | 2021-07-08 | 2022-07-08 | ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250179498A1 (enExample) |
| EP (1) | EP4368717A1 (enExample) |
| JP (1) | JP7853399B2 (enExample) |
| KR (1) | KR20230010593A (enExample) |
| CN (1) | CN117677697A (enExample) |
| AU (1) | AU2022308807B2 (enExample) |
| CA (1) | CA3225054A1 (enExample) |
| WO (1) | WO2023282704A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250137186A (ko) * | 2023-03-08 | 2025-09-17 | 올릭스 주식회사 | 비만의 예방 또는 치료용 RNAi 제제 및 이를 이용한 병용 요법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090905A1 (es) * | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| EA038792B1 (ru) * | 2013-05-22 | 2021-10-20 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US10835581B2 (en) * | 2017-11-28 | 2020-11-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method of treating insulin resistance |
| WO2020123410A1 (en) * | 2018-12-10 | 2020-06-18 | Amgen Inc. | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
| WO2020154567A1 (en) * | 2019-01-25 | 2020-07-30 | Viscient Biosciences, Inc. | Compositions and methods for the diagnosis and treatment of diseases of the liver |
| US12215382B2 (en) * | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| US20230183707A1 (en) * | 2020-05-21 | 2023-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| KR20230046319A (ko) * | 2020-08-13 | 2023-04-05 | 암젠 인크 | MARC1 발현을 억제하기 위한 RNAi 작제물 및 방법 |
| EP4347820A1 (en) * | 2021-05-28 | 2024-04-10 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression |
-
2022
- 2022-07-08 CA CA3225054A patent/CA3225054A1/en active Pending
- 2022-07-08 WO PCT/KR2022/009984 patent/WO2023282704A1/ko not_active Ceased
- 2022-07-08 CN CN202280048413.XA patent/CN117677697A/zh active Pending
- 2022-07-08 EP EP22838056.4A patent/EP4368717A1/en active Pending
- 2022-07-08 US US18/577,278 patent/US20250179498A1/en active Pending
- 2022-07-08 AU AU2022308807A patent/AU2022308807B2/en active Active
- 2022-07-08 JP JP2024500173A patent/JP7853399B2/ja active Active
- 2022-07-08 KR KR1020220084498A patent/KR20230010593A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106255755B (zh) | 用于调节血管生成素样蛋白3表达的组合物和方法 | |
| CN107236735B (zh) | 包含锁核酸基序的基于寡核苷酸的抑制剂 | |
| JP2025019119A (ja) | ケイ素を含有するカチオン性脂質 | |
| TW202024324A (zh) | 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法 | |
| TW202323524A (zh) | Ｈｂｂ—調節組合物及方法 | |
| PT2015758E (pt) | Compostos e métodos para modular a expressão da proteína apob | |
| JP6396891B2 (ja) | 遺伝子改変コクサッキーウイルス | |
| JP2016520312A5 (enExample) | ||
| JP2017509354A5 (enExample) | ||
| CN115397436A (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| JP2016523548A (ja) | 成長ホルモン受容体のモジュレータ | |
| CA3147643A1 (en) | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression | |
| CN117295819A (zh) | 用于抑制补体组分3表达的组合物和方法 | |
| WO2013056670A1 (zh) | 小干扰RNA及其应用和抑制plk1基因表达的方法 | |
| JP2024525078A5 (enExample) | ||
| JP2023533124A (ja) | 二本鎖オリゴヌクレオチド及びこれを含むコロナウイルス感染症－１９（ｃｏｖｉｄ－１９）治療用組成物 | |
| JP7106788B2 (ja) | Ｍｅｘ３ｂ遺伝子の発現を抑制する核酸、ｍｅｘ３ｂ遺伝子発現抑制剤、ｍｅｘ３ｂ遺伝子発現を抑制する方法及びｍｅｘ３ｂ遺伝子発現に起因する疾病の予防又は治療剤 | |
| JP2024506882A (ja) | 化学修飾された低分子活性化ｒｎａ | |
| TW201119681A (en) | Compositions and methods for inhibiting expression of KIF10 genes | |
| JP2022064910A (ja) | 副腎脊髄ニューロパチーの治療のためのａｂｃｄ１をコードする核酸配列の髄腔内送達 | |
| WO2022026648A1 (en) | Inhibition of incexact1 to treat heart disease | |
| JP7853399B2 (ja) | ＭＡＲＣ１遺伝子を標的にするＲＮＡｉ製剤及びその用途 | |
| WO2016077704A1 (en) | Modulation of agpat5 expression | |
| JP2024529930A5 (enExample) | ||
| WO2022270071A1 (ja) | 肝線維化抑制のための剤及び医薬組成物 |